UPB
Upstream Bio, Inc.
Healthcare — Biotechnology
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Buy
1.6 / 5
8 analysts
$5.04
$-0.23 (-4.36%)
Target:
$38.25
(658.9%)
Price History
52-Week Range
Sign in to add UPB to a watchlist or set price alerts.
Fundamentals
| Market Cap | $398.63M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.54 |
| EPS (TTM) | $-2.90 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 82.70% |
| ROE | -41.83% |
| Debt/Equity | 0.37 |
| Recommendation | Buy 1.6 |
| Analyst Target | $38.25 |
| Analysts | 8 |
| Next Earnings | Aug 11, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 75.1 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $33.68 |
| 52-Week Low | $5.85 |
| 50-Day Avg | $7.95 |
| 200-Day Avg | $17.10 |
| Avg Volume | 572.5K |
| Volume | 656.7K |
Performance Analysis
BULLISHUPB shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($5.85), which could present a value opportunity.
-
RSI at 75.1 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 82.7% year-over-year.
+
Wall Street consensus is "Buy" from 8 analysts.
+
Average analyst target of $38.25 implies 658.9% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:35 UTC
Back to Screener Export Report